J.P. Morgan Life Sciences Personal Capital, the NYC-based life sciences enterprise and development fairness arm inside J.P. Morgan Asset Administration, introduced the appointment of Dashyant Dhanak, Ph.D., as Enterprise Accomplice.
Dr. Dhanak is a seasoned pharmaceutical analysis and growth knowledgeable with over 30 years of expertise. Most not too long ago, he was the Chief Scientific Officer at Deciphera Prescribed drugs, which was acquired by Ono Prescribed drugs in 2024. Previous to his position at Deciphera, Dr. Dhanak served as Chief Scientific Officer at Incyte, the place he was accountable for overseeing the analysis and preclinical growth of modern medicines throughout the corporate’s hematology, oncology, and immunology franchises. Throughout his tenure at Incyte, Dr. Dhanak contributed considerably to the submitting of over fifteen Investigational New Drug (IND) purposes. Earlier than becoming a member of Incyte in 2018, he was Vice President and International Head of Discovery Sciences at Johnson & Johnson’s (J&J) Janssen Analysis & Improvement group. Previous to J&J, he spent 25 years at GlaxoSmithKline.
J.P. Morgan Life Sciences Personal Capital is the life sciences platform of J.P. Morgan Personal Capital, the funding arm for personal firms throughout the capital construction with a deal with enterprise and development investing inside J.P. Morgan Asset Administration. The agency companions with early-stage biotherapeutics and late-stage healthcare firms.
FinSMEs
19/05/2025
